Equity Profile

CNTA

Centessa Pharmaceuticals plc

Health CareBiotechnology$6.3B

Aug11Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Centessa Pharmaceuticals plc is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, it aims to address unmet medical needs through its diverse pipeline of drug candidates.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

$-0.39

Revenue

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CNTA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-51.59%

Avg Stock Reaction

+6.48%

Last Quarter Recap

In Q1-2026, Centessa reported an EPS of $-0.52, which was worse than the expected $-0.38, resulting in a 36.84% negative surprise. The stock reacted with a slight decline of 0.08% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts anticipate another challenging quarter for Centessa, with expectations of a loss per share of $-0.39. Investors will be closely watching for any signs of progress in the company's drug development pipeline.

Bull Case

If Centessa can exceed EPS expectations and provide positive updates on its clinical trials, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet EPS expectations again or provides no clarity on its future revenue, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$-0.39

Earnings per share is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Centessa's EPS come in better than the expected $-0.39?

A better-than-expected EPS could signal improved operational efficiency and boost investor confidence.

What updates can Centessa provide regarding its drug development pipeline?

Investors are keen to understand the progress of clinical trials, which could impact future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Centessa to surprise on EPS given recent advancements in its drug pipeline.

Supporting Evidence

The options market is pricing a significant move, indicating that traders expect volatility that could favor a positive surprise.

Centessa's historical performance shows that it has occasionally exceeded expectations, suggesting potential upside.

Key Risk

If the EPS comes in better than $-0.39, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on whether Centessa can turn around its earnings trend and provide clarity on its future growth prospects.

Bull Confirmed If

An EPS of better than $-0.39 alongside positive updates on drug trials would confirm the bull case.

Bear Confirmed If

An EPS worse than $-0.39 with no new information on the pipeline would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.42%

Historical Avg

±8.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±17.4% while CNTA has averaged ±8.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

2.5%

Calls (5K)P/C Ratio: 27.83Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Centessa beats expectations, history suggests a potential stock increase of around 0.04%, confirming a positive outlook.

In-Line / Cautious

Should the results come in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of about 8.63%, reflecting ongoing concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the timelines for drug trial results.
2Updates on partnerships or collaborations that could enhance revenue potential.
3Insights into cost management strategies that could improve EPS.
4Details on any upcoming product launches or regulatory approvals.
5Management's outlook on market conditions affecting the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

$-0.39

Revenue

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CNTA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-51.59%

Avg Stock Reaction

+6.48%

Last Quarter Recap

In Q1-2026, Centessa reported an EPS of $-0.52, which was worse than the expected $-0.38, resulting in a 36.84% negative surprise. The stock reacted with a slight decline of 0.08% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Centessa can exceed EPS expectations and provide positive updates on its clinical trials, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet EPS expectations again or provides no clarity on its future revenue, it could lead to further declines in stock price.

Key Metrics to Watch

EPS

$-0.39

Earnings per share is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Centessa's EPS come in better than the expected $-0.39?

A better-than-expected EPS could signal improved operational efficiency and boost investor confidence.

What updates can Centessa provide regarding its drug development pipeline?

Investors are keen to understand the progress of clinical trials, which could impact future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Centessa to surprise on EPS given recent advancements in its drug pipeline.

Supporting Evidence

The options market is pricing a significant move, indicating that traders expect volatility that could favor a positive surprise.

Centessa's historical performance shows that it has occasionally exceeded expectations, suggesting potential upside.

Key Risk

If the EPS comes in better than $-0.39, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on whether Centessa can turn around its earnings trend and provide clarity on its future growth prospects.

Bull Confirmed If

An EPS of better than $-0.39 alongside positive updates on drug trials would confirm the bull case.

Bear Confirmed If

An EPS worse than $-0.39 with no new information on the pipeline would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.42%

Historical Avg

±8.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±17.4% while CNTA has averaged ±8.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

2.5%

Calls (5K)P/C Ratio: 27.83Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Centessa beats expectations, history suggests a potential stock increase of around 0.04%, confirming a positive outlook.

In-Line / Cautious

Should the results come in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of about 8.63%, reflecting ongoing concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the timelines for drug trial results.
2Updates on partnerships or collaborations that could enhance revenue potential.
3Insights into cost management strategies that could improve EPS.
4Details on any upcoming product launches or regulatory approvals.
5Management's outlook on market conditions affecting the biotechnology sector.